
    
      This trial is a Phase I dose escalation study aiming to evaluate the safety of a combined
      treatment associating HDM201 (escalating doses) with Trametinib (fixed dose). This study will
      utilize sequential and adaptive Bayesian design using the method of Time-to-event Continual
      Reassessment Method (CRM) to guide dose escalation and estimate the MTD.
    
  